Teachers Retirement System of The State of Kentucky Buys 120,500 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Teachers Retirement System of The State of Kentucky increased its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 318.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 158,300 shares of the company’s stock after buying an additional 120,500 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Roivant Sciences were worth $1,674,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Roivant Sciences during the 2nd quarter worth $34,000. Point72 Hong Kong Ltd bought a new position in Roivant Sciences during the second quarter worth about $36,000. Quarry LP purchased a new position in shares of Roivant Sciences in the second quarter worth about $53,000. Acadian Asset Management LLC bought a new stake in shares of Roivant Sciences in the first quarter valued at approximately $72,000. Finally, Fifth Third Wealth Advisors LLC purchased a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $101,000. Institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In related news, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the transaction, the director now owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the completion of the transaction, the director now directly owns 22,179,358 shares of the company’s stock, valued at approximately $262,160,011.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares in the company, valued at approximately $210,693,701.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,477,309 shares of company stock valued at $40,986,184 in the last 90 days. Insiders own 4.60% of the company’s stock.

Roivant Sciences Stock Performance

ROIV stock opened at $11.38 on Friday. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.06. The stock’s 50 day simple moving average is $11.55 and its 200 day simple moving average is $11.12. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $8.41 billion, a PE ratio of 2.25 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. During the same quarter last year, the firm posted ($0.38) earnings per share. The firm’s revenue was up 155.1% compared to the same quarter last year. As a group, research analysts forecast that Roivant Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America increased their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $17.39.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.